Chloroquine and Hydroxychloroquine-Related Ocular Adverse Events in SLE Treatment: A Real-World Disproportionality Analysis Based on FDA Adverse Event Reporting System (FAERS) Author

Xiang Li^1,2*Shi-Nan Wu^1,2Zhang Siqi³Mengyuan Wang^1,2Cui-Ting Chen^1,2Tao Tao^1,2Nuo Dong¹

• ¹Eye Center, Xiamen University, Xiamen, China
• ²Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, College of Medicine, Xiamen University, Xiamen, Fujian Province, China
• ³School of Medicine, Xiamen University, Xiamen, Fujian, China

Objective: This study aimed to evaluate the risk of adverse events associated with chloroquine (CQ) and hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus (SLE), using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: Disproportionality analysis was conducted using the Reporting Odds Ratio (ROR) to detect potential safety signals. Sensitivity analyses were performed to validate these signals, and the time to onset for each Preferred Term (PT) was assessed. Results: Between 2004 and 2024, a total of 2,575 adverse event reports related to HCQ or CQ use in patients with SLE were identified in the FAERS database, of which 437 involved ocular adverse events. The most frequently reported ocular conditions were cataract, macular degeneration, and glaucoma. Disproportionality analysis demonstrated strong associations between HCQ/CQ use and retinal degeneration (ROR = 28.5, 95%CI: 19.94 -40.74 ), cystoid macular oedema (ROR = 12.46, 95%CI: 8.01 -19.37), and optic atrophy (ROR = 6.55, 95%CI: 3.51 -12.19 ).Sensitivity analyses, conducted after excluding SLE cases, indicated that all but one event (vitreous floaters) remained statistically significant, suggesting that these risks are more likely attributable to HCQ/CQ exposure than to the underlying disease. The time-to-onset analysis showed that cataract had the shortest average onset time (125.5 days), whereas retinal degeneration had the longest (937.5 days).The extensive clinical use of HCQ and CQ raises significant concerns regarding their ocular safety profile. This study provides real-world pharmacovigilance evidence supporting a substantial risk of ocular adverse events associated with HCQ/CQ use. Further mechanistic and prospective studies are warranted to elucidate the underlying pathophysiological pathways and to confirm these associations.